Royal Bank of Canada’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$409K Sell
40,994
-25,206
-38% -$251K ﹤0.01% 4294
2025
Q4
$655K Buy
+66,200
New +$654K ﹤0.01% 3961

Other funds holding DMII

Royal Bank of Canada's DMII Position: Q1 2026 in Review

Royal Bank of Canada reduced its Drugs Made In America Acquisition II Corp (DMII) stake by 38% in Q1 2026, selling an estimated $251K and leaving 40,994 shares worth $409K. The position accounts for ﹤0.01% of the portfolio, ranked #4294.

Royal Bank of Canada first reported a position in DMII in Q4 2025 and has held it in 2 quarters since. The position peaked at $655K in Q4 2025. 68 funds tracked by Wall St. Rank hold DMII as of Q1 2026.

  • Royal Bank of Canada held 40,994 shares of Drugs Made In America Acquisition II Corp worth $409K as of Q1 2026.
  • Royal Bank of Canada sold 25,206 Drugs Made In America Acquisition II Corp shares in Q1 2026, an estimated $251K.
  • Drugs Made In America Acquisition II Corp made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4294 holding.
  • Royal Bank of Canada first reported a position in Drugs Made In America Acquisition II Corp in Q4 2025 and has held it in 2 quarters since.
  • Royal Bank of Canada's Drugs Made In America Acquisition II Corp position peaked at $655K in Q4 2025.
  • 68 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.